Search Results
Oct 14, 2025, 02:20 ET 華上生醫抗癌新藥GNTbm-TKI將在ESMO發表
模型中，和免疫缺陷小鼠相比，在野生型小鼠（免疫健全）中顯示出優異的體內抗癌療效，顯示GNTbm-TKI的優越抗癌活性與免疫活化有關。此外，GNTbm-TKI 與 GNTbm-38（屬於第I 類 HDAC 抑制劑的免疫活化劑）並聯合 ICI 的組合治療，通過協同作用顯著提升腫瘤反應率和生存率，推測其可能的機制包括: 讓腫瘤血管正常化、增加活化 CD8+ T 及吸引細胞浸潤至腫瘤微環境中、誘導記憶 T 細胞的生成，以及強力抑制免疫抑制型細胞被腫瘤吸引至腫瘤微環境中。另一方面，研究也顯示GNTbm-TKI + GNTbm-38 聯合抗 PD-1/VEGF 雙特異性抗體，在人源化 B-PD-1/PD-L1/VEGFA 小鼠模型中，也極大地改善了抗癌效果，表現出強烈的協同增效作用。
More news about: 華上生醫
Oct 14, 2025, 02:19 ET Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
significantly improved tumor response rate and boosted survival rate through synergistic effect by normalizing tumor vessels, increasing activated CD8+ T cell infiltration into tumors, inducing memory T cell persistence, and strongly inhibiting mobilization of immunosuppressive cells into tumors.
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Oct 13, 2025, 14:34 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP
Oct 13, 2025, 12:10 ET Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 10:57 ET U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
the gastrointestinal (GI) tract. Crohn's disease (CD) and ulcerative colitis (UC) are the most common forms of IBD. In both CD and UC, the immune system causes inflammation and damage to the mucosa – or lining – of the gut.1,2,3 Specifically, CD manifests as inflammation within the GI tract,
More news about: AbbVie
Oct 13, 2025, 08:30 ET Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 07:30 ET ADC Therapeutics Announces $60 Million Private Placement
About ZYNLONTA ® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The
More news about: ADC Therapeutics SA
Oct 09, 2025, 08:30 ET American Securities and CD&R Complete $8.8B Foundation Building Materials Sale
said Tyler Young, Principal at CD&R. "We believe FBM will be an outstanding platform in partnership with Lowe's to serve pro customers and build on long-standing supplier relationships." Under the ownership of American Securities and CD&R, FBM became an industry leader,
More news about: American Securities LLC
Oct 09, 2025, 08:22 ET Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
cells for rapid and potent immune activation [3]—but also minimizes PD-1-mediated recruitment of the co-stimulatory molecule CD28, thereby preserving CD28 signaling [4-6], enhancing downstream AKT activity [7], and promoting sustained T-cell activation. The ASTRUM-006
More news about: Henlius
Oct 09, 2025, 07:38 ET 開創無化療時代：全球首個H藥胃癌圍手術期III期臨床研究達到主要終點，支持提前申報上市
[4] Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-1433.
More news about: 復宏漢霖
Oct 08, 2025, 16:30 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP
Oct 08, 2025, 10:58 ET Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
updates anticipated in the first quarter of 2026. The Phase 1 trial is testing GTB-3650 in patients with relapsed or refractory CD33-expressing blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These are patients whose cancers have
More news about: Equity Insider
Oct 08, 2025, 09:11 ET CD Valet Expands Marketplace and Enhances Intelligence Tool, Offering Most Comprehensive View of Today's CD Market
About CD Valet CD Valet is a digital marketplace that connects consumers with top CD rates from banks and credit unions nationwide and enables financial institutions to efficiently and cost-effectively attract retail deposits. With CD Valet, banks and
More news about: CD Valet
Oct 08, 2025, 08:30 ET ImmunoVec Launches from Stealth with up to $40.7 Million ARPA-H EMBODY Award to Advance In Vivo Cell Engineering Platform for Autoimmune Diseases
ARPA-H-funded project will apply the company's platform to develop a novel polymeric nanoparticle capable of engineering natural killer (NK) cells in vivo with a CD19-targeted chimeric antigen receptor (CAR) construct. This approach aims to deplete B cells that cause autoimmune disease (autoreactive cells), and offers
More news about: ImmunoVec
Oct 08, 2025, 08:00 ET Biond Biologics Announces Initiation of a Phase 2 Study of BND-22 in Combination with anti-PD-1 therapy
trial dose escalation as of May 2024. Biond is also developing BND-67, a first-in-class antibody, that specifically prevents the shedding CD28 from T cells. Blocking CD28 shedding drives prolonged T cell activation and enables safe and sustained immune responses. This unique approach can overcome resistance
More news about: Biond Biologics Ltd.
Oct 08, 2025, 08:00 ET BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Oct 07, 2025, 20:15 ET CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
refractory, 10 (50%) had received autologous stem cell transplantation (ASCT), and 5 (25%) had relapsed after CAR T-cell therapies targeting BCMA or BCMA/CD19. Four (20%) patients had extramedullary disease (EMD), 14 (70%) had ≥1 high-risk cytogenetics and 19 (95%) had a Revised International Staging System
More news about: CARsgen Therapeutics
Oct 07, 2025, 17:30 ET BIOVAXYS ANNOUNCES LIFE OFFERING
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
(GTB-5550) and autoimmune indications (GTB-7550)." The Phase 1 trial is testing GTB-3650 in patients with relapsed or refractory CD33-expressing blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These are patients whose cancers have
More news about: USA News Group
Oct 07, 2025, 08:05 ET TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory
More news about: Johnson & Johnson
Oct 07, 2025, 08:05 ET Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
Johnson & Johnson has initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC as well as the ICONIC-CD Phase 2b/3 protocol in adults with moderately to severely active Crohn's disease.2,3 Icotrokinra is also being studied in the pivotal
More news about: Johnson & Johnson
Oct 07, 2025, 08:01 ET Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
T cells and T cell subsets: Increases were noted in total T cell numbers, CD8 and CD4 T cell subsets, and tumor specific T cells (CD137 +ve) in participants following Hemopurifier treatment without a consistent pattern in terms of timing of improvement.
More news about: Aethlon Medical, Inc.
Oct 07, 2025, 08:00 ET Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
(GTB-5550) and autoimmune indications (GTB-7550)." The Phase 1 trial is testing GTB-3650 in patients with relapsed or refractory CD33-expressing blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These are patients whose cancers have
More news about: Equity Insider
Oct 07, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
NCT06937086) and COMMIT-CD (
More news about: Eli Lilly and Company
Oct 07, 2025, 06:30 ET Austin's Haute Spot hosts "Ryan's Day 15" featuring Wheelz the Rapper and Plain White T's - Sun. Oct 26th
T's, We The Kings, Lixbox, and Hannah & Curt Jones. In addition to the above listed activities and treats, Ryan's latest CD, "Music Saved My Life" will be available for purchase, as well as his 3 full length CD's: "In The Beginning," "Determined," and "2Determined."
More news about: Inspiration on Wheelz